Daniel Stetson
YOU?
Author Swipe
View article: Data from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Data from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Background: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutin…
View article: Supplementary Data 1 from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data 1 from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic …
View article: Supplementary Data 1 from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data 1 from Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic …
View article: Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer Open
PURPOSE Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS A total of 156 …
View article: Primary cilia are critical for tracheoesophageal septation
Primary cilia are critical for tracheoesophageal septation Open
Introduction Primary cilia play pivotal roles in the patterning and morphogenesis of a wide variety of organs during mammalian development. Here we examined murine foregut septation in the cobblestone mutant, a hypomorphic allele of the ge…
View article: Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic …
View article: Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic …
View article: Data from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Data from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Purpose:Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib h…
View article: Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic …
View article: Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Supplementary Data Supplementary Table 1: Key exclusion criteria Supplementary Table 2: Prior systemic therapies Supplementary Table 3: Subsequent anticancer therapy Supplementary Table 4: Mutations by response: cell-of-origin and genetic …
View article: Data from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Data from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Background:Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutini…
View article: Data from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Data from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Purpose:Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib h…
View article: Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment Open
Purpose: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib …
View article: Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests
Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests Open
The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium is a collaborative effort involving stakeholders from the public, industry, academia, and regulatory agencies focused on developing shared best practices on liquid biopsy. This repo…
View article: Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples
Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples Open
Background Clinical laboratories routinely use formalin-fixed paraffin-embedded (FFPE) tissue or cell block cytology samples in oncology panel sequencing to identify mutations that can predict patient response to targeted therapy. To under…
View article: Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Open
PURPOSE To examine the prevalence and dynamics of circulating tumor DNA (ctDNA) and its association with metastatic recurrence in patients with high-risk early-stage hormone receptor–positive breast cancer (HR+ BC) more than 5 years from d…
View article: Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models Open
Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR-mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the acquired resistance mechanisms…
View article: Additional file 2 of Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples
Additional file 2 of Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples Open
Additional file 2. A multiple tab Microsoft Excel file of FFPE experiment information, extensive quality check data and analysis results for FFPE samples, and analysis results for free DNA samples.
View article: Additional file 3 of Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples
Additional file 3 of Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples Open
Additional file 3. List of known variants for four participating oncology panels.
View article: Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health Open
PURPOSE We report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This a…
View article: Deep oncopanel sequencing reveals fixation time- and within block position-dependent quality degradation in FFPE processed samples
Deep oncopanel sequencing reveals fixation time- and within block position-dependent quality degradation in FFPE processed samples Open
Clinical laboratories routinely use formalin-fixed paraffin-embedded (FFPE) tissue or cell block cytology samples in oncology panel sequencing to identify mutations that can predict patient response to targeted therapy. To understand the t…
View article: Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial Open
PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has …
View article: Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance
Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance Open
PURPOSE Discordance between plasma and tumor variant calling has been attributed primarily to tumor heterogeneity, whereas technical variables remain largely unexplored. MATERIALS AND METHODS To measure these variables, we tested four next…
View article: Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients
Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients Open
Background: Recent studies demonstrated profound clinical activity of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients. However, the emergence of resistance limits the clinical benef…
View article: Peer Review #2 of "Prioritisation of structural variant calls in cancer genomes (v0.2)"
Peer Review #2 of "Prioritisation of structural variant calls in cancer genomes (v0.2)" Open
Sensitivity of short read DNA-sequencing for gene fusion detection is improving, but is hampered by the significant amount of noise composed of uninteresting or false positive hits in the data.In this paper we describe a tiered prioritisat…